Onconova Therapeutics Inc (ONTX)

[@LiftedCapital]

Onconova Therapeutics to Present at the 30th Annual Roth Conference in MarchSource: GlobeNewswire Inc.


Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), will present at the 30th Annual Roth conference taking place on March 11-13 at The Ritz Carlton Hotel in Dana Point, California. The Company’s Chief Medical Officer, Dr. Steven Fruchtman, will present and be available for one-on-one meetings.

Presentation Details:

Date: Monday, March 12th, 2018

Time: 7:00 am PT

Location: The Ritz Carlton in Dana Point, Salon 6

The presentation will be available here on the Company’s website.

About Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS).  Rigosertib, Onconova's lead candidate, is a proprietary Phase 3 small molecule agent, which the Company believes blocks cellular signaling by targeting RAS effector pathways.  Using a proprietary chemistry platform, Onconova has created a pipeline of targeted agents designed to work against specific cellular pathways that are important in cancer cells.  Onconova has three product candidates in the clinical stage and several pre-clinical programs.  Advanced clinical trials with the Company’s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS.  For more information, please visit http://www.onconova.com.